OvaScience to Present at the Oppenheimer Annual Healthcare Conference

OvaScience, Inc.Theresa McNeely, Head of Corporate Communications617-299-7356

, (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, will present at the Oppenheimer 23rd Annual Healthcare Conference at the Waldorf Astoria Hotel in New York City on Wednesday, December 12, 2012 at 1:35 p.m. ET.

A webcast of the presentation can be accessed by visiting the Investor section of the Company’s website at . A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation date.

OvaScience (OTC: OVSC) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company’s patented technology is based on the discovery of egg precursor cells (EggPC), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT aims to improve egg quality and increase the success of fertilization (IVF). OvaScience’s team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit .

Suggested Articles

Orum Therapeutics raised $30 million to expand the applications for for its cell-penetrating antibody technology.

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.